SCHEMBL13767008

SCHEMBL13767008

O=C(NC1C2CC3CC(C2)CC1C3)c1cnn(CCO)c1OCC(F)(F)F

nearest known ligand 0.46

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 16/20 0.46
HTT P42858 1/20 0.42
LMNA P02545 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13767050 0.88 HSD11B1 (0.48) HSD11B1HTT
SCHEMBL13767055 0.86 HSD11B1 (0.42) HSD11B1HTTLMNA
SCHEMBL13767261 0.86 HSD11B1 (0.42) HSD11B1HTTLMNA
SCHEMBL13767006 0.84 HSD11B1 (0.46) HSD11B1HTTLMNA
SCHEMBL13767073 0.84 HSD11B1 (0.42) HSD11B1HTTLMNA
SCHEMBL13766835 0.83 HSD11B1 (0.48) HSD11B1HTTLMNA
SCHEMBL13767291 0.83 HSD11B1 (0.41) HSD11B1HTTLMNA
SCHEMBL13767072 0.83 HSD11B1 (0.40) HSD11B1HTTLMNA
SCHEMBL13766705 0.82 EPHX2 (0.47) HSD11B1
SCHEMBL13766709 0.82 HSD11B1 (0.44) HSD11B1HTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324265-B2 Heterocyclic compounds having type I 11β hydroxysteroid dehydrogenase inhibitory activity SHIONOGI & CO., LTD. (JP) 2012-12-04 US disclosed
US-8324265-B2 Heterocyclic compounds having type I 11β hydroxysteroid dehydrogenase inhibitory activity SHIONOGI & CO., LTD. (JP) 2012-12-04 US disclosed
US-20090170832-A1 HETEROCYCLIC COMPOUNDS HAVING TYPE I 11beta HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY SHIONOGI & CO., LTD. (JP) 2009-07-02 US disclosed
US-20090170832-A1 HETEROCYCLIC COMPOUNDS HAVING TYPE I 11beta HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY SHIONOGI & CO., LTD. (JP) 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170832-A1 HETEROCYCLIC COMPOUNDS HAVING TYPE I 11beta HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY HSD17B1, HSD11B1, HSD3B1 HSD11B1 2/4885HTT 3719/4885LMNA 2271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.